Comment
doi: 10.1016/j.ahj.2011.04.024.
Epub 2011 May 31.
Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease
- PMID: 21742076
- DOI: 10.1016/j.ahj.2011.04.024
Item in Clipboard
Comment
Liver transaminase levels alone could not be the optimal method to estimate hepatic safety after statin administration in patients with chronic kidney disease
Am Heart J.
2011 Jul.
No abstract available
Comment on
-
Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.Am Heart J. 2010 Nov;160(5):785-794.e10. doi: 10.1016/j.ahj.2010.08.012. Epub 2010 Sep 18. Am Heart J. 2010. PMID: 21095263 Clinical Trial.
Similar articles
-
Statin effects in CKD: is there a "point of no return"?Am J Kidney Dis. 2009 May;53(5):723-5. doi: 10.1053/j.ajkd.2009.02.002. Am J Kidney Dis. 2009. PMID: 19393469 No abstract available.
-
Impact of statin dosing intensity on transaminase and creatine kinase.Am J Med. 2008 Feb;121(2):e11; author reply e13. doi: 10.1016/j.amjmed.2007.09.018. Am J Med. 2008. PMID: 18261479 No abstract available.
-
Safety of statin therapy in patients with preexisting liver disease.Pharmacotherapy. 2008 Apr;28(4):522-9. doi: 10.1592/phco.28.4.522. Pharmacotherapy. 2008. PMID: 18363535 Review.
-
The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.Clin J Am Soc Nephrol. 2011 Mar;6(3):664-78. doi: 10.2215/CJN.09091010. Epub 2011 Mar 10. Clin J Am Soc Nephrol. 2011. PMID: 21393488 Review.
-
Statins and the liver.Cardiol Clin. 2015 May;33(2):257-65. doi: 10.1016/j.ccl.2015.02.005. Cardiol Clin. 2015. PMID: 25939298 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
